Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Turkish Version of the Ankle Fracture Outcome of Rehabilitation Measure (A-FORM-TR): A Multi-Centre Validation Study (A-FORM-TR)

2. September 2026 aktualisiert von: Utku Gürhan

Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of the Ankle Fracture Outcome of Rehabilitation Measure (A-FORM-TR): A Multi-Centre Prospective Observational Study

Ankle fractures are common injuries that can affect a patient's mobility, mood, sleep, and everyday life for months. The Ankle Fracture Outcome of Rehabilitation Measure (A-FORM) is an English-language patient-reported outcome measure developed in Australia to capture this broader rehabilitation experience. No validated Turkish version of A-FORM currently exists. This prospective multi-centre observational study aims to translate the A-FORM into Turkish (A-FORM-TR), culturally adapt it for use in Turkish-speaking patients, and evaluate its psychometric properties. The investigators will recruit 150 adults with a unilateral ankle fracture, treated either surgically or conservatively, from three orthopedic centres in Turkiye and the Turkish Republic of Northern Cyprus. Participants complete the A-FORM-TR together with two established comparator questionnaires (AOFAS Ankle-Hindfoot Score and the Turkish Olerud-Molander Ankle Score). A subset of approximately 50 participants is re-administered the A-FORM-TR after 7 to 14 days to assess test-retest reliability, with a Global Rating of Change item identifying clinically stable patients. Analyses include classical test theory, confirmatory factor analysis, and Rasch measurement analysis.

Studienübersicht

Status

Rekrutierung

Detaillierte Beschreibung

Background and Rationale: Ankle fractures are among the most common lower-limb injuries in orthopedic practice. Patient-reported recovery, including physical function, sleep, mood, and social participation, is not adequately captured by traditional clinician-based outcome measures such as the AOFAS Ankle-Hindfoot Score or the Olerud-Molander Ankle Score. The A-FORM, developed by McPhail et al. (2014), is a 15-item, Rasch-calibrated patient-reported outcome measure designed specifically to evaluate the rehabilitation experience after ankle fracture. No validated Turkish-language version currently exists.

Methodological Framework: The study follows the eight-stage cross-cultural adaptation and validation protocol described by Cruchinho et al. (2024), which incorporates the recommendations of Beaton et al. (2000) and the COSMIN framework (Mokkink et al., 2010). Written permission to translate and use the instrument has been granted by Prof. Steven McPhail (Queensland University of Technology).

Translation and Adaptation: Forward translation is carried out by two independent bilingual translators (one faculty member from the Department of English Language and Literature, providing linguistic expertise; one bilingual orthopedic surgeon, providing clinical content expertise). A reconciliation committee produces a synthesised Turkish version, which is then back-translated by two independent translators blinded to the original. A harmonisation expert committee compares the source, forward, and back versions for semantic, idiomatic, experiential, and conceptual equivalence. The harmonised pre-test version is evaluated through cognitive debriefing interviews with 10 to 15 ankle-fracture patients before field testing.

Field Testing: In the field testing phase, 150 adult patients with a radiographically confirmed unilateral ankle fracture (Weber A, B, or C; treated surgically by open reduction and internal fixation or conservatively with cast, walker boot, or functional brace) are enrolled across three orthopedic centres. Patients between 3 weeks and 12 months post-injury are eligible. The A-FORM-TR is administered together with the AOFAS Ankle-Hindfoot Score and the OMAS-TR. A sub-cohort of approximately 50 patients is re-administered the A-FORM-TR at 7 to 14 days, with a Global Rating of Change item used to identify clinically stable patients for the test-retest reliability analysis.

Statistical Analysis Plan: The analysis plan was locked before any field data were collected; all decision rules are pre-specified. Developed in consultation with the institutional biostatistics team. Internal consistency is assessed by Cronbach's alpha (target greater than or equal to 0.80). Test-retest reliability is assessed by the intraclass correlation coefficient on stable patients, reported with the K-index (greater than or equal to 0.70 acceptable for group-level comparison, greater than or equal to 0.90 desirable for individual-level decisions). Measurement error is evaluated separately from reliability as the standard error of measurement and the smallest detectable change. Rasch measurement analysis is the primary framework and examines item fit, threshold ordering, person separation reliability, person-item targeting, local independence, unidimensionality, and differential item functioning by sex, age group, treatment modality, recruiting centre, and time since injury; pre-specified decision rules govern the handling of item misfit, disordered thresholds and differential item functioning. Confirmatory factor analysis provides a complementary structural test of the prespecified single-factor model, with exploratory factor analysis run as a supplementary check. Construct validity is assessed via pre-specified hypotheses about correlation patterns with the AOFAS and OMAS-TR, and by known-groups comparison across time-since-injury strata. Criterion validity is assessed in a bilingual sub-study of approximately 30 participants completing both the A-FORM-TR and the original English-language A-FORM in counterbalanced order, with agreement quantified by correlation, intraclass correlation and Bland-Altman analysis. Responsiveness is assessed at 3 months against a Global Rating of Change anchor using the standardised response mean (SRM), effect size and receiver operating characteristic (ROC) analysis, with the minimal important change compared against the smallest detectable change. Cross-cultural measurement invariance is examined against the original English calibration, conditional on the source data available from the instrument developer. Content validity is assessed via item-level and scale-level Content Validity Index and the Kappa coefficient from the expert committee. Floor and ceiling effects are examined at the scale level. Missing data are reported per item; the primary analysis is complete-case, with multiple imputation as a sensitivity analysis where item-level missingness exceeds 5 percent.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

150

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Cankara
      • Ankara, Cankara, Türkei (türkiye), 6600
        • Rekrutierung
        • Ankara Bilkent City Hospital - Department of Orthopaedics and Traumatology
        • Kontakt:
        • Unterermittler:
          • Yakup Kahve, MD
      • Kyrenia, Zypern
        • Rekrutierung
        • University of Kyrenia, Dr. Suat Gunsel Hospital - Department of Orthopaedics and Traumatology
        • Kontakt:
        • Hauptermittler:
          • Utku Gurhan, MD
      • Nicosia, Zypern
        • Rekrutierung
        • Near East University Hospital - Department of Orthopaedics and Traumatology
        • Unterermittler:
          • Enes Sari, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adult patients presenting to the orthopedic outpatient clinics of three participating hospitals (University of Kyrenia, Dr. Suat Gunsel Hospital, Turkish Republic of Northern Cyprus; Ankara Bilkent City Hospital, Turkiye; Near East University Hospital, Turkish Republic of Northern Cyprus) for follow-up of a unilateral ankle fracture in the rehabilitation phase 3 weeks to 12 months post-injury, treated either surgically or conservatively.

Beschreibung

Inclusion Criteria:

  • Age 18 years or older
  • Radiographically confirmed unilateral ankle fracture (Weber A, B, or C)
  • Either surgical (open reduction and internal fixation) or conservative (cast, walker boot, or functional brace) treatment completed
  • Currently in the rehabilitation phase, 3 weeks to 12 months post-injury
  • Native Turkish speaker, able to read and self-complete a questionnaire
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Bilateral ankle fracture
  • Previous ipsilateral ankle fracture or any prior orthopedic surgery on the same ankle
  • Pathological fracture (tumour, metastasis, or other underlying bone pathology)
  • Concurrent significant ipsilateral lower-limb injury (for example pilon fracture, ipsilateral tibial or fibular shaft fracture, ipsilateral femoral or tibial plateau fracture)
  • Polytrauma (significant head, spine, abdominal, or contralateral lower-limb injury affecting function)
  • Cognitive or psychiatric impairment precluding self-completion of the questionnaire
  • Insufficient Turkish literacy
  • Inability to attend a follow-up visit for the test-retest assessment

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Internal consistency of the A-FORM-TR
Zeitfenster: At the single study visit (baseline administration)
Cronbach's alpha coefficient calculated across all scored items of the A-FORM-TR. Target greater than or equal to 0.80.
At the single study visit (baseline administration)
Test-retest reliability of the A-FORM-TR
Zeitfenster: Second administration at day 7 and third administration at day 14 after baseline
Intraclass correlation coefficient (two-way mixed effects, absolute agreement, single measures) calculated for the A-FORM-TR Summary Score, restricted to patients reporting clinical stability (no change) on a Global Rating of Change item. The K-index of agreement is reported alongside the ICC. Thresholds: greater than or equal to 0.70 acceptable for group-level comparison; greater than or equal to 0.90 desirable for individual-level decisions.
Second administration at day 7 and third administration at day 14 after baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Construct validity assessed by a priori hypothesis testing
Zeitfenster: At the single study visit (baseline administration)
Pearson or Spearman correlations between the A-FORM-TR Summary Score and the AOFAS Ankle-Hindfoot Score and OMAS-TR. Pre-specified hypotheses: H1, strong positive correlation between A-FORM-TR and OMAS-TR (r greater than or equal to 0.60); H2, moderate positive correlation between A-FORM-TR and AOFAS (r between 0.40 and 0.60); H3, the psychosocial items of the A-FORM-TR correlate more weakly with the AOFAS than the physical-function items. Construct validity is considered supported if at least 75 percent of the a priori hypotheses are confirmed.
At the single study visit (baseline administration)
Content validity of the A-FORM-TR
Zeitfenster: Pre-testing phase, prior to field testing
Item-level and scale-level Content Validity Index and the Kappa coefficient of agreement derived from the expert committee evaluation conducted in the pre-testing phase.
Pre-testing phase, prior to field testing
Distribution properties: floor and ceiling effects
Zeitfenster: At the single study visit (baseline administration)
Percentage of participants scoring at the floor (lowest possible score) and ceiling (highest possible score) of the A-FORM-TR Summary Score. Effects are considered acceptable if less than 15 percent at either extreme.
At the single study visit (baseline administration)
Rasch model fit of the A-FORM-TR
Zeitfenster: At the single study visit (baseline administration)
Rasch measurement analysis serves as the primary framework for evaluating dimensionality and measurement properties of the A-FORM-TR. Examined: item fit (infit and outfit mean-square 0.5 to 1.5), category threshold ordering, person separation reliability (target greater than or equal to 2.0), local independence (residual correlations less than 0.30), unidimensionality (residual principal component analysis first contrast less than 2.0), and differential item functioning by sex, age group, treatment modality, centre, and time since injury. A priori decision rules: items showing substantive misfit will be reviewed for rescoring or removal; disordered thresholds will trigger response category collapsing and re-analysis; items showing significant DIF will be split or removed and the analysis re-run on the modified scale.
At the single study visit (baseline administration)
Structural validity by confirmatory factor analysis
Zeitfenster: At the single study visit (baseline administration)
Confirmatory factor analysis testing the prespecified single-factor (unidimensional) structure established in the original A-FORM development by McPhail et al. (2014). CFA serves as a complementary structural check from a latent-variable perspective alongside the primary Rasch analysis. Model fit assessed by CFI and TLI (target greater than or equal to 0.95), RMSEA (target less than or equal to 0.08), and SRMR (target less than or equal to 0.08).
At the single study visit (baseline administration)
Known-groups validity by time since injury and treatment modality
Zeitfenster: At the single study visit (baseline administration)
Known-groups validity assessed by testing whether A-FORM-TR Summary Scores differ across pre-specified clinical subgroups. Pre-specified hypotheses: H4, patients in the 3-week to 3-month post-injury subgroup will score significantly lower (greater impairment) than patients in the 6- to 12-month subgroup; H5, A-FORM-TR Summary Scores will differ between surgically treated and conservatively treated patients (no a priori directional hypothesis). Analyses by independent-samples t-test or Mann-Whitney U as appropriate, with Cohen's d or effect size reporting. Added in response to peer review feedback from the original instrument developer.
At the single study visit (baseline administration)
Measurement error of the A-FORM-TR
Zeitfenster: Between baseline and the day 14 administration
Standard error of measurement (SEM) derived from the test-retest data, and the smallest detectable change (SDC) calculated as 1.96 x square root of 2 x SEM. Bland-Altman plots with limits of agreement are reported. Measurement error is evaluated as a property distinct from reliability, in line with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework.
Between baseline and the day 14 administration
Responsiveness of the A-FORM-TR
Zeitfenster: Baseline and 3 months
Ability of the A-FORM-TR to detect change over time, assessed against an anchor. Change scores from baseline to 3 months are correlated with a single-item Global Rating of Change (expected r greater than or equal to 0.50). The standardised response mean (SRM) and effect size are computed separately in patients reporting improvement and in those reporting no change (expected SRM greater than or equal to 0.80 versus less than 0.20). Discrimination between improved and stable patients is assessed by receiver operating characteristic (ROC) analysis, with the area under the curve (AUC) expected to be greater than or equal to 0.70. The minimal important change derived from the ROC optimal cut-point is compared against the smallest detectable change.
Baseline and 3 months
Criterion validity against the original English A-FORM
Zeitfenster: Baseline (Day 1); both language versions administered in the same session, at least 30 minutes apart
In a bilingual sub-study of approximately 30 Turkish Cypriot participants who are functionally literate in both Turkish and English, both the A-FORM-TR and the original English-language A-FORM are administered in counterbalanced order with at least 30 minutes between administrations. Agreement between the two language versions is assessed by Pearson or Spearman correlation (expected r greater than or equal to 0.80), intraclass correlation coefficient (expected greater than or equal to 0.80), and Bland-Altman analysis to detect systematic differences. Bilingual eligibility requires documented criteria beyond self-report. This subgroup is not representative of the main sample and this is reported as a limitation.
Baseline (Day 1); both language versions administered in the same session, at least 30 minutes apart
Cross-cultural measurement invariance
Zeitfenster: At the single study visit (baseline administration)
Comparison of the Turkish item calibration against the original English-language calibration reported by McPhail et al. 2014. The analysis is conditional on the level of source data available from the instrument developer: with raw item-level data, multi-group confirmatory factor analysis testing configural, metric and scalar invariance; with item difficulty estimates only, anchored Rasch calibration with comparison of item difficulty hierarchies. If neither is available, within-sample differential item functioning by sex, age group, treatment modality, recruiting centre and time since injury is reported together with a descriptive comparison against the published psychometric profile.
At the single study visit (baseline administration)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Utku Gurhan, MD, University of Kyrenia

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

24. Juli 2026

Primärer Abschluss (Geschätzt)

1. April 2027

Studienabschluss (Geschätzt)

1. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

20. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Mai 2026

Zuerst gepostet (Tatsächlich)

2. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • AFORM-TR-2026
  • ETK26-GD-0094 (Andere Kennung: Girne University Clinical Research Ethics Committee)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

De-identified participant-level data will be made available upon reasonable request to the corresponding author after publication, subject to institutional and ethics-committee approval. Aggregated summary tables will accompany the published manuscript as supplementary material.

IPD-Sharing-Zeitrahmen

Beginning 6 months after manuscript publication, with no specified end date.

IPD-Sharing-Zugriffskriterien

Reasonable request for academic research purposes; a data use agreement to be signed.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren